Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00−0.06 (-6.10%)
Close on Nov 17, 2026Market cap $35.42MP/E –Yield –
Skye Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Skye Bioscience's operating income for the twelve months ending Jun 30, 2026 was -$51.90M. For fiscal 2025 it was -$58.16M. The highest annual figure on record is $4.12K in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.16M | – |
| FY2024 | Dec 31, 2024 | -$30.19M | – |
| FY2023 | Dec 31, 2023 | -$34.74M | – |
| FY2022 | Dec 31, 2022 | -$18.31M | – |
| FY2021 | Dec 31, 2021 | -$7.85M | – |
| FY2020 | Dec 31, 2020 | -$6.29M | – |
| FY2019 | Dec 31, 2019 | -$6.63M | – |
| FY2018 | Dec 31, 2018 | -$4.69M | – |
| FY2017 | Dec 31, 2017 | -$3.86M | – |
| FY2016 | Dec 31, 2016 | -$4.47M | – |
| FY2015 | Dec 31, 2015 | -$4.32M | – |
| FY2013 | Oct 31, 2013 | -$3.78K | -191.9% |
| FY2012 | Oct 31, 2012 | $4.12K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.67M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.76M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.67M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.41M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.09M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.84M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.10M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.89M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.54M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.21M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.84M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.77M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.32M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.05M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.25M | – |
| Q4 FY2017 | Dec 31, 2017 | -$986.52K | – |
| Q3 FY2017 | Sep 30, 2017 | -$761.63K | – |
| Q2 FY2017 | Jun 30, 2017 | -$730.93K | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.38M | – |
| Q4 FY2016 | Dec 31, 2016 | -$912.06K | – |
| Q3 FY2016 | Sep 30, 2016 | -$856.15K | – |
See a number that looks wrong?